Peña-Bates Carlos, Ramón-Luing Lucero A, Flores-Gonzalez Julio, Espinosa Enrique, Martinez-Moreno María F, Medina-Quero Karen, Vargas-Hernandez Marco A, Téllez-Navarrete Norma A, Sosa-Gomez Fernando M, Becerril-Vargas Eduardo, Salazar Miguel Ángel, Chavez-Galan Leslie
Laboratory of Integrative Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
Laboratory of Immunology, Escuela Militar de Graduados de Sanidad, Universidad del Ejército y Fuerza Aérea Mexicanos, Mexico City, Mexico.
Front Immunol. 2025 May 19;16:1566449. doi: 10.3389/fimmu.2025.1566449. eCollection 2025.
INTRODUCTION: The chronic nature of latent tuberculosis infection (LTBI) allows it to coexist with diverse pathologies. However, it remains unclear whether immune alterations associated with LTBI influence COVID-19 coinfection and patient outcomes. This study aims to compare the immune phenotype of patients with LTBI/COVID-19 to those with COVID-19 alone, in order to assess whether latent tuberculosis infection induces significant immune cell alterations. METHODS: Peripheral blood mononuclear cells were cultured and stimulated with the SARS-CoV-2 Spike protein and Bacillus Calmette-Guérin ( BCG) to evaluate cellular distribution and function. RESULTS: the LTBI/COVID-19 group exhibited a narrower range of symptoms and required less complex treatment regimens than the COVID-19 group. The cellular evaluation revealed that individuals with COVID-19 displayed a distinct immune profile, characterized by a predominance of monocytes expressing pro-inflammatory and regulatory markers, including TNFR2, HLA-DR+TNFR2, and CD71. While CD4+ T cell subpopulation distribution and function were similar across groups, LTBI/COVID-19 and COVID-19 exhibited similar frequencies of CD8+perforin+ and CD8+Granzime B+ T cells. However, LTBI/COVID-19 displays lower soluble levels of granzyme B and perforin in culture supernatants and perforin, granulysin, and sFas in plasma compared to COVID-19. Notably, CD8+ T cells from LTBI/COVID-19 showed higher antigen-specific degranulation than COVID-19. Moreover, LTBI/COVID-19 individuals predominantly displayed CD4+ and CD8+ T cells with highly polarized, compact mitochondria at baseline, which remained unchanged under stimulation. In contrast, COVID-19 had T cells with highly polarized, fragmented mitochondria at baseline, a profile that persisted under stimulation. CONCLUSION: The findings reveal significant alterations in monocytes and T cells of individuals with LTBI/COVID-19, suggesting that co-infection may induce changes in the cellular phenotype and cytotoxic function of CD8 T cells.
引言:潜伏性结核感染(LTBI)的慢性性质使其能够与多种病理状况共存。然而,与LTBI相关的免疫改变是否会影响新冠病毒合并感染及患者预后仍不清楚。本研究旨在比较LTBI/新冠病毒合并感染患者与单纯新冠病毒感染患者的免疫表型,以评估潜伏性结核感染是否会引起显著的免疫细胞改变。 方法:培养外周血单个核细胞,并用严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白和卡介苗(BCG)进行刺激,以评估细胞分布和功能。 结果:与新冠病毒感染组相比,LTBI/新冠病毒合并感染组症状范围更窄,所需治疗方案更简单。细胞评估显示,新冠病毒感染个体表现出独特的免疫特征,其特征是表达促炎和调节标志物(包括肿瘤坏死因子受体2(TNFR2)、HLA-DR+TNFR2和CD71)的单核细胞占主导。虽然各组间CD4+T细胞亚群分布和功能相似,但LTBI/新冠病毒合并感染组和新冠病毒感染组的CD8+穿孔素+和CD8+颗粒酶B+T细胞频率相似。然而,与新冠病毒感染组相比,LTBI/新冠病毒合并感染组培养上清液中颗粒酶B和穿孔素以及血浆中穿孔素、颗粒溶素和可溶性Fas(sFas)的可溶性水平较低。值得注意的是,LTBI/新冠病毒合并感染组的CD8+T细胞显示出比新冠病毒感染组更高的抗原特异性脱颗粒。此外,LTBI/新冠病毒合并感染个体在基线时主要表现为具有高度极化、紧密线粒体的CD4+和CD8+T细胞,在刺激下保持不变。相比之下,新冠病毒感染个体在基线时具有高度极化、碎片化线粒体的T细胞,这种特征在刺激下持续存在。 结论:研究结果揭示了LTBI/新冠病毒合并感染个体单核细胞和T细胞的显著改变,表明合并感染可能会诱导CD8 T细胞的细胞表型和细胞毒性功能发生变化。
AIDS Res Hum Retroviruses. 2024-7
Int J Infect Dis. 2021-12
Front Immunol. 2020-2-7
Clin Transl Immunology. 2025-1-25
BMC Infect Dis. 2024-11-4
Vaccines (Basel). 2024-9-30
Hum Vaccin Immunother. 2024-12-31
Front Biosci (Landmark Ed). 2024-9-24